PT  - JOURNAL ARTICLE
AU  - Azahari Kasbollah
AU  - Peter Eu
AU  - Simon Cowell
AU  - Pradip Deb
TI  - Review on Production of <sup>89</sup>Zr in a Medical Cyclotron for PET Radiopharmaceuticals
AID  - 10.2967/jnmt.112.111377
DP  - 2013 Mar 01
TA  - Journal of Nuclear Medicine Technology
PG  - 35--41
VI  - 41
IP  - 1
4099  - http://tech.snmjournals.org/content/41/1/35.short
4100  - http://tech.snmjournals.org/content/41/1/35.full
SO  - J. Nucl. Med. Technol.2013 Mar 01; 41
AB  - This article is intended to provide an overview of the production and application of 89Zr for the professional development of nuclear medicine technologists. It outlines the cyclotron targeting, separation and labeling options, and techniques for the preparation of the radionuclide 89Zr (half-life, 78.4 h [3.3 d]) used in PET. Unlike the commonly used 18F-FDG, with a 109.7-min half-life, the longer half-life of 89Zr makes it possible to use high-resolution PET/CT to localize and image tumors with monoclonal antibody radiopharmaceuticals and thus potentially expand the use of PET. Methods: This paper briefly reviews the cyclotron technique of 89Zr production and outlines the range and preparation techniques available for making 89Y targets as a starting material. It then discusses how cyclotron-produced 89Zr can be separated, purified, and labeled to monoclonal antibodies for PET/CT of specific tumors. Results: We argue that knowledge and understanding of this long-lived PET radionuclide should be part of the professional development of nuclear medicine technologists because it will lead to better patient outcomes and potentially increase the pool of collaborators in this field of research.